|
|
86 Morris Avenue
Summit, NJ 07901 USA
phone:908-673-9000
fax:708-555-5467
|
|
| Symbol |
CELG |
| Exchange |
Nasdaq |
| Founded |
1980 |
| Employees |
|
|
|
| www.celgene.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drugs for cancer and inflammatory conditions |
|
| Management |
| Sol J. Barer, Ph.D., Chairman and Chief Executive Officer; Robert J. Hugin, President and Chief Operating Officer; Michael D. Casey, Former President and Chief Executive Officer of Matrix Pharmaceutical, Inc.; Rodman L. Drake, Managing Director CIP Management; Arthur Hull Hayes, Jr., M.D.Former President & COO MediScience Associates |
| |
|
|
|
|
|
|
|
| Keywords |
| lenalidomide, thalidomide, azacitidine, placental, thalomid |
|
|
|
| Description |
|
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide. Celgene seeks to deliver truly innovative and life-changing drugs for our patients. Their mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. |
|
| Products / Services |
The company's leading products include REVLIMID (lenalidomide), THALOMID (thalidomide), ALKERAN (melphalan), FOCALIN (dexmethylphenidate HCl), cellular and tissue therapeutics, as well as the Ritalin family of drugs.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
